Document Type : Original Article
Authors
- Javad Javan-Noughabi 1
- Sayed Ali Mousavi 2
- Seyed Yaser Hashemi 3
- Ahmad Faramarzi 4
- Farshad Bahrami Asl 5
- Hamidreza Shabanikiya 6
1 Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Health, Shoushtar Faculty of Medical Science, Shoushtar, Iran
3 Fasa University of Medical Sciences, Fasa, Iran
4 Department of Health Management and Economics, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran
5 Department of Environmental Health Engineering, School of Health, Urmia University of Medical Sciences, Urmia, Iran
6 Department of Health Economics and Management Sciences, Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Background: Coronavirus disease 2019 (COVID-19) has posed an unusual threat to global health. Up to May 26, 2021, according to a report by the World Health Organization (WHO), 167.01 million cases, and 3.47 million deaths were reported. This study aimed to estimate and compare epidemiological indices of COVID-19 in high-incidence countries.
Methods: We conducted a descriptive and comparative analysis intending to examine the epidemiological indices of COVID- 19 in high-incidence countries, using the data published by the WHO until May 17, 2021. We calculated the incidence and mortality rate per 1,000,000 inhabitant-day at risk daily, weekly, and overall, using person-day as the denominator.
Results: The fatality rate in 14 countries was about 1.94%. The highest fatality rate was acquired in Italy (2.99%), followed by the United Kingdom (2.86%) and Iran (2.79%). The lowest value on the fatality rate was in Turkey and India, at 0.88% and 1.1%. The highest incidence rate was reported in the USA (207 cases per 1,000,000 person-day), followed by France (190), Poland (171), and Argentina (167). The highest mortality rate for the whole period was extracted in Brazil (4.60 death per 1,000,000 population-day), and the lowest rate happened in India (0.42).
Conclusion: Until May 17, 2021, COVID-19 has affected about 117.6 million patients and caused 2.3 million deaths in 14 highincidence countries. This study shows that a specific pattern of COVID-19 has been observed in every country.
Keywords
- ul Qamar MT, Alqahtani SM, Alamri MA, Chen L-L. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313-9. doi: 10.1016/j.jpha.2020.03.009. PMID: 32296570.
- Ornell F, Schuch JB, Sordi AO, Kessler FHP. “Pandemic fear” and COVID-19: mental health burden and strategies. Braz J Psychiatry. 2020;42(3):232-5. doi: 10.1590/1516-4446-2020-0008. PMID: 32267343.
- Kandel N, Chungong S, Omaar A, Xing J. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. The Lancet. 2020;395(10229):1047-53. doi: 10.1016/S0140-6736(20)30553-5. PMID: 32199075.
- Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23(8):468-78. doi: 10.1016/j.tim.2015.06.003. PMID: 26206723.
- Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26(5):483-95. doi: 10.1016/j.molmed.2020.02.008. PMID: 32359479.
- Lai C-C, Wang C-Y, Wang Y-H, Hsueh S-C, Ko W-C, Hsueh P-R. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946. doi: 10.1016/j.ijantimicag.2020.105946. PMID: 32199877.
- Chih-Cheng L, Cheng-Yi W, Ya-Hui W, Shun-Chung H, Wen-Chien K, Po-Ren H. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55. doi: 10.1016/j.ijantimicag.2020.105946. PMID: 32199877.
- Rodriguez-Villamizar LA, Belalcázar-Ceron LC, Fernández-Niño JA, Marín-Pineda DM, Rojas-Sánchez OA, Acuña-Merchán LA, et al. Air pollution, sociodemographic and health conditions effects on COVID-19 mortality in Colombia: an ecological study. Sci Total Environ. 2021;756:144020. doi: 10.1016/j.scitotenv.2020.144020. PMID: 33279185.
- Wildman J. COVID-19 and income inequality in OECD countries. Eur J Health Econ. 2021;22(3):455-62. doi: 10.1007/s10198-021-01266-4. PMID: 33590424.
- Mokhtari AM, Susan Dewey R, Mirahmadizadeh A. The Global Challenges of Controlling Coronavirus Disease 2019: A Review Study. Journal of Health Sciences & Surveillance System. 2021;9(3):142-8. doi: 10.30476/jhsss.2021.90136.1179.
- Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. Lancet Infect Dis. 2020;20(8):e198-e203. doi: 10.1016/S1473-3099(20)30438-2. PMID: 32479747.
- Coronavirus Disease (COVID-19) Dashboard. 2021. Available from: https://covid19.who.int/table.
- Baldwin R, Weder di Mauro B. Economics in the Time of COVID-19. CEPR Press; 2020.
- Kharas H, Hamel K. IMF’s World Economic Outlook, Initial Assessment of a country-by-country of what might happen to the world economy in 2020 and 2021. IMF; 2020.
- Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020:105955. doi: 10.1016/j.ijantimicag.2020.105955. PMID: 32234468.
- Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268-71. doi: 10.34172/aim.2020.09. PMID: 32271601.
- Roosa K, Lee Y, Luo R, Kirpich A, Rothenberg R, Hyman J, et al. Real-time forecasts of the COVID-19 epidemic in China from February 5 to February 24, 2020. Infect Dis Model. 2020;5:256-63. doi: 10.1016/j.idm.2020.02.002.
- United Nations. World Population Prospects 2019. 2020. Available from: http://creativecommons.org/licenses/by/3.0/igo/.
- Li Lq, Huang T, Wang Yq, Wang Zp, Liang Y, Huang Tb, et al. COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis. J Med Virol. 2020;92(6):577-83. doi: 10.1002/jmv.25757. PMID: 32162702.
- Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: discovery, diagnostics and drug development. J Hepatol. 2020. doi: 10.1016/j.jhep.2020.09.031. PMID: 33038433.
- Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Hanses F. [Epidemiology of SARS-CoV-2 infection and COVID-19]. Internist (Berl). 2020;61(8):782-8. doi: 10.1007/s00108-020-00834-9. PMID: 32548652.
- He W, Yi GY, Zhu Y. Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID‐19: Meta‐analysis and sensitivity analysis. J Med Virol. 2020;92(11):2543-50. doi: 10.1002/jmv.26041. PMID: 32470164.
- Cao Y, Hiyoshi A, Montgomery S. COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data. BMJ open. 2020;10(11):e043560. doi: 10.1136/bmjopen-2020-043560. PMID: 33148769.
- Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. Eur Rev Med Pharmacol Sci. 2020;24(23):12593-608. doi: 10.26355/eurrev_202012_24057. PMID: 33336780.
- Buja A, Paganini M, Cocchio S, Scioni M, Rebba V, Baldo V. Demographic and socio-economic factors, and healthcare resource indicators associated with the rapid spread of COVID-19 in Northern Italy: An ecological study. PLoS One. 2020;15(12):e0244535. doi: 10.1371/journal.pone.0244535. PMID: 33370383.
- Shahrajabian MH, Sun W, Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother. 2020:1-22. doi: 10.1080/21645515.2020.1797369. PMID: 32783700.
- Update 49 - SARS case fatality ratio, incubation period. 2003. Available from: https://www.who.int/csr/sars/ archive/2003_05_07a/en/.
- Donnelly C, Malik M, Elkholy A, Cauchemez S, Van Kerkhove M. Important reductions in the global number of MERS cases and deaths since 2016. Emerg Infect Dis. 2019;25(9). doi: 10.3201/eid2509.190143. PMID: 31264567.
- Lai C-C, Wang C-Y, Wang Y-H, Hsueh P-R. Global coronavirus disease 2019: What has daily cumulative index taught us? Int J Antimicrob Agents. 2020;55(6):106001. doi: 10.1016/j.ijantimicag.2020.106001. PMID: 32360230.
)